





Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : bobE48670

Collected : 25/Nov/2023 09:08AM

Received : 25/Nov/2023 02:22PM

Reported : 25/Nov/2023 05:46PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

METHODOLOGY

: Microscopic

RBC MORPHOLOGY

: Predominantly normocytic normochromic RBC's noted.

WBC MORPHOLOGY

: Normal in number, morphology and distribution. No abnormal cells seen.

PLATELETS

: Adequate in number.

PARASITES

: No haemoparasites seen

IMPRESSION

: Normocytic Normochromic blood picture

NOTE/ COMMENT

: Please correlate clinically.

Page 1 of 14











: Mr.SATHYA NARAYANAN S

Age/Gender

: 34 Y 1 M 16 D/M : CANN.0000229734

UHID/MR No Visit ID

Ref Doctor

: CANNOPV380085

Emp/Auth/TPA ID

: Dr.SELF : bobE48670 Collected : 25/Nov/2023 09:08AM

Received : 25/Nov/2023 02:22PM

Reported : 25/Nov/2023 05:46PM Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY				
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

HEMOGRAM , WHOLE BLOOD EDTA				- 1 4
HAEMOGLOBIN	13.8	g/dL	13-17	Spectrophotometer
PCV	40.50	%	40-50	Electronic pulse & Calculation
RBC COUNT	4.79	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	84.6	fL	83-101	Calculated
MCH	28.9	pg	27-32	Calculated
MCHC	34.1	g/dL	31.5-34.5	Calculated
R.D.W	13.1	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	7,300	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DL	-C)			
NEUTROPHILS	58.7	%	40-80	Electrical Impedance
LYMPHOCYTES	31.4	%	20-40	Electrical Impedance
EOSINOPHILS	2.4	%	1-6	Electrical Impedance
MONOCYTES	6.8	%	2-10	Electrical Impedance
BASOPHILS	0.7	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4285.1	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2292.2	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	175.2	Cells/cu.mm	20-500	Calculated
MONOCYTES	496.4	Cells/cu.mm	200-1000	Calculated
BASOPHILS	51.1	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	199000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	8	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

METHODOLOGY

: Microscopic

RBC MORPHOLOGY

: Predominantly normocytic normochromic RBC's noted.

WBC MORPHOLOGY

: Normal in number, morphology and distribution. No abnormal cells seen.

PLATELETS


: Adequate in number.

PARASITES

: No haemoparasites seen

Page 2 of 14













: Mr.SATHYA NARAYANAN S

Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No Visit ID

: CANN.0000229734

Ref Doctor

: CANNOPV380085

Emp/Auth/TPA ID

: Dr.SELF

: bobE48670

Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 02:22PM : 25/Nov/2023 05:46PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

IMPRESSION

: Normocytic Normochromic blood picture

NOTE/ COMMENT

: Please correlate clinically.

Page 3 of 14











Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor

: Dr.SELF Emp/Auth/TPA ID : bobE48670 Collected : 25/Nov/2023 09:08AM

Received : 25/Nov/2023 02:22PM

Reported : 25/Nov/2023 07:17PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324						
Test Name Result Unit Bio. Ref. Range Method						

BLOOD GROUP ABO AND RH FAC	TON, WHOLL BLOOD LDTA	
BLOOD GROUP TYPE	0	Microplate Hemagglutination
Rh TYPE	Positive	Microplate Hemagglutination

Page 4 of 14





SIN No:BED230289480
This test has been performed at Apollo Health and Lifestyle Ltd - RRL ASHOK NAGAR
This test has been performed at Apollo Health and Lifestyle Ltd - Chennai, Diagnostics Laboratory. Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)





Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: bobE48670

Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 02:49PM

Reported Status

: 25/Nov/2023 03:18PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY FILL BODY ANNUAL DILIS MALE

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

GLUCOSE, FASTING, NAF PLASMA	103	mg/dL	70-100	HEXOKINASE

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 5 of 14







Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No Visit ID

: CANN.0000229734

Ref Doctor

: CANNOPV380085

: Dr.SELF Emp/Auth/TPA ID : bobE48670

Test Name

Collected : 25/Nov/2023 12:32PM

Received : 25/Nov/2023 04:53PM

Reported : 25/Nov/2023 05:38PM Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY						
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Rio Ref Range	Method		

GLUCOSE, POST PRANDIAL (PP), 2	93	mg/dL	70-140	HEXOKINASE
HOURS, SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 6 of 14











Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : bobE48670 Collected : 25/Nov/2023 09:08AM

Received : 25/Nov/2023 02:21PM

Reported : 25/Nov/2023 05:41PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT	OF	BIOCH	EMISTRY	

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		

			· · · · · · · · · · · · · · · · · · ·	
HBA1C, GLYCATED HEMOGLOBIN,	5.7	%		HPLC
WHOLE BLOOD EDTA				
ESTIMATED AVERAGE GLUCOSE (eAG),	117	mg/dL		Calculated

Comment:

WHOLE BLOOD EDTA

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 - 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 - 8	Ţ.
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 7 of 14







Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: bobE48670

Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 02:51PM : 25/Nov/2023 04:37PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	149	mg/dL	<200	CHO-POD
TRIGLYCERIDES	56	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	36	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	113	mg/dL	<130	Calculated
LDL CHOLESTEROL	101.8	mg/dL	<100	Calculated
VLDL CHOLESTEROL	11.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.14		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 8 of 14

SIN No:SE04550053
This test has been performed at Apollo Health and Lifestyle Ltd. RRL ASHOK NAGAR This test has been performed at Apollo Health and Lifestyle Ltd. - Chennai, Diagnostics Laboratory.

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang ww.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744







Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: bobE48670

Collected : 25/Nov/2023 09:08AM

Received : 25/Nov/2023 02:51PM

Reported : 25/Nov/2023 04:37PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY				
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324				
Test Name Result Unit Bio. Ref. Range Method				

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.51	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.11	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.40	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	11	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	13.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	77.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.10	g/dL	6.6-8.3	Biuret
ALBUMIN	4.30	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.80	g/dL	2.0-3.5	Calculated
A/G RATIO	1.54		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 9 of 14



SIN No:SE04550053
This test has been performed at Apollo Health and Lifestyle Ltd. RRL ASHOK NAGAR. This test has been performed at Apollo Health and Lifestyle Ltd. - Chennai, Diagnostics Laboratory.

Apollo Health and Lifestyle Limited (CIN - U85110TG2000PLC115819)
Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang

Pho

D No.30, F - Block 2nd Avenue, Anna Nagar East, Chennai.600 102 Phone : 044.26224504 / 05







Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : bobE48670

Test Name

Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 02:51PM

Reported Status

: 25/Nov/2023 04:37PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 Unit Result Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM				
CREATININE	0.78	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	20.00	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	9.4	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.50	mg/dL	3.5–7.2	Uricase PAP
CALCIUM	9.20	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.60	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	139	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.0	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	104	mmol/L	101–109	ISE (Indirect)

Page 10 of 14









: Mr.SATHYA NARAYANAN S

Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No Visit ID

: CANN.0000229734

Ref Doctor

: CANNOPV380085

Emp/Auth/TPA ID

: Dr.SELF

: bobE48670

Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 02:51PM : 25/Nov/2023 04:11PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name Result	Unit	Bio. Ref. Range	Method
------------------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	14.00	U/L	<55	IFCC	
(GGT) , SERUM					

Page 11 of 14

1860



SIN No:SE04550053
This test has been performed at Apollo Health and Lifestyle Ltd., RRL ASHOK NAGAR. This test has been performed at Apollo Health and Lifestyle Ltd. - Chennai, Diagnostics Laboratory.

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)







Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No

: CANN.0000229734

Visit ID

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: bobE48670

Collected : 25/Nov/2023 09:08AM

Received : 25/Nov/2023 02:42PM

Reported : 25/Nov/2023 03:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY				
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH),	SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	0.95	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	8.80	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	1.620	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	Т4	FT4	Conditions	
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	Subclinical Hyperthyroidism	
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	Thyroiditis, Interfering Antibodies	
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	

Page 12 of 14













: Mr.SATHYA NARAYANAN S

Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No Visit ID

: CANN.0000229734

Ref Doctor

: CANNOPV380085

Emp/Auth/TPA ID

: Dr.SELF : bobE48670 Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 04:51PM : 25/Nov/2023 06:15PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 **Test Name** Unit Result Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (CU	JE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY	1		
PUS CELLS	2-4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-3	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 13 of 14



SIN No: UR 2226760
This test has been performed at Apollo Health and Lifestyle Ltd. RRL ASHOK NAGAR This test has been performed at Apollo Health and Lifestyle Ltd. - Chennai, Diagnostics Laboratory.





: Mr.SATHYA NARAYANAN S

Age/Gender

: 34 Y 1 M 16 D/M

UHID/MR No Visit ID

: CANN.0000229734

: CANNOPV380085

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: bobE48670

Collected

: 25/Nov/2023 09:08AM

Received

: 25/Nov/2023 01:52PM : 25/Nov/2023 02:39PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

ARCOFEMI - MEDIWHEEL	FULL BODY ANNUAL PLUS MA	ALE - TMT - PAN INDIA - FY2324
AINOUI LIVII - WILDIVVIILLE	I OLL DOD! ANNOAL! LOO MA	

Test Name Unit Bio. Ref. Range Method Result

URINE GLUCOSE(POST PRANDIAL) **NEGATIVE NEGATIVE** Dipstick

URINE GLUCOSE(FASTING) **NEGATIVE NEGATIVE** Dipstick

*** End Of Report ***

Dr.MARQUESS RAJ

M.D,DipRCPath,D.N.B(PATH) Consultant Pathologist

DR.R.SRIVATSAN M.D.(Biochemistry) Dr THILAGA

M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 14 of 14





Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819) Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangi www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

SIN No: UPP015838. UF009841
This test has been performed at Apollo Health and Lifestyle Ltd - RRL ASHOK NAGAR
This test has been performed at Apollo Health and Lifestyle Ltd - Chennai, Diagnostics Laboratory.

UHID : CANN.0000229734 OP Visit No : CANNOPV380085 Reported By: : Dr. ARULNITHI AYYANATHAN Conducted Date : 26-11-2023 13:16

Referred By : SELF

ECG REPORT

Observation:


1. Heart rate is 76beats per minutes.

Impression:

SINUS ARRHYTHMIA.

---- END OF THE REPORT -----

Dr. ARULNITHI AYYANATHAN



CANN-229784 OCR-97304



& July.





ds/u/23

Mr. Lathe	Janaraya	nan 34)	М
Height:	Weight:	BMI:	Waist Circum:
Temp:	Pulse:	Resp:	B.P:

General Examination / Allergies History

Patient advised scaling, restorations, & extraction of

Follow up date:

Doctor Signature & Stamp

Convenient & reliable. Complete diagnostic services for the entire family. All under one roof.



OPHTHALMOLOGY




Name: Sathya harayo Occupation: Age: Sex: Male Fei Address: Ph:	maie□ Ref. Physicia	Tulos Reg. No.: 299 7341
REPO	ORT ON OPHTHALMIC EX	AMINATION
History: Ex islies	glass usos	poist 18 years.
Present Complaint:	ble coeffs coeff glass	presert glass. BE 616
ON EXAMINATION:	RE	LE
Ocular Movements : Anterior Segment :	Treu	Free
Intra-Ocular-Pressure : Visual Acuity: D.V. :		N
Without Glass :	N	10
With Glass:		6/12
N.V. :	61.	11/2
Visual Fields :	1112	Nb
Fundus :	6/12 No	
Impression:	Lui	Ful.
Advice :		N.
Colour Vision :	N	OPHTHALMOLOGY / OPTOMETRIST













Apollo Clinic

CONSENT FORM

Patient Name:	Sothya	Age:	34/M.
UHID Number:	2 29734	Company Name	34/H. Arcopeni
I Mr/Mrs/Ms	Saray.	Employee of	Arcopeni Eug on Luie
(Company) Want to	inform you that I am not	interested in getting	Eug on Luie
	a part of my routine healt		
And I claim the abo	ve statement in my full co	nsciousness.	
Patient Signature:	& Laguey	Date:	25/11/23

No. 30, F-Block, 2nd Avenue,
Anna Nagar East, Chennai-600 102
Anna Nagar East, Chennai-600 102
Tel: 044-26224505, Mobile: 7358392880
Tol: No. 1860 500 7788

Apollo Health and Lifestyle Limited (CIN - U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK

O No.30, F.—Block 2nd Arenue, Anna Nagar Fast, Chement 600 102, Phone 044-26224504/05



*	MR SATHYA	MR SATHYA NARAYANAN S,	ś			Tabular Summary	mmary					A	POLLO ME	APOLLO MEDICAL CENTRE	TRE
	Patient ID 229734 RMC 25.11.2023 Male	34 RMC Male						BRUCE: To	BRUCE: Total Exercise Time 12:05 Max HR: 184 bpm 98% of max predicted 186 bpm	Time 12:0	5 edicted 186		HR at rest: 75		ia.
r	1:16:37pm	34yrs Indian Meds:						Max BP: 15 Maximum	Max BP: 150/90 mmHg BP at res Maximum Workload: 11:90 METS	BP at res	BP at rest: 120/80 00 METS	Max RPP: 2	Max RPP: 25060 mmHg*bpm	mdd*g	
		Test Reason: Medical History:						Max. ST: -(Arrhythmia	Max. ST: -0.60 mm, 0.00 mV/s in III; EXEKCISE STAGE + 11.57 Arrhythmia: A:187, PVC:6, PSVC:12, ESC:2	C:6, PSV	III; EXERC C:12, ESC	15E 51 AU	t 2		
								Reasons for	Reasons for Termination: Leg discomion Conclusion: FINAL IMPRESSION: TMT IS NEGATIVE / POSITIVE FOR	on: Leg dis PRESSION	COMION N. TMT IS	NEGATIVE	VITASON/	EFOR	
		Ref. MD: Or	Ordering MD:					INDUCIBI	NDUCIBLE MYOCARDIAL ISCHEMIA	EDIAL ISC	HEMIA				
		Comment:												\	
													X	<u></u>	
	Phase Name	Stage Name	Time in Stage	Speed (mph)	Grade (%)	Workload (METS)	HR (bpm) (BP (mmHg) (RPP (mmHg*bpm	VE (/min)	ST Level (III mm)	Comment	8		
	PRETEST	SUPINE	00:02	00.00	00.00	1.0	7.5			0	1				
	I WEI CO	STANDING	10:00	0.00	0.00	1:0	75			0	1 3				
		WARM-UP	00:45	1.00	0.00	<u></u>	74	120/80	8880	> c	0.00				
	EXERCISE	STAGE 1	03:00	0.7 0.8 0.8	8.6	A 0 9	011	120/80	14640	0	0.55				
		STAGE 2 STAGE 3	03:00	3.40	00.11	8.7	153	130/80	19890	0	-0.10				
		STAGE 4	03:00	4.20	13.00	11.7	184	140/90	25760	8.	-0.30				
		STAGE 5	50:00	2.00	15.00	6 . -	184	00/001	0,000	- c	0.00				
	RECOVERY		04:26	0.00	0.00	0.1	2	130,80	12740	2) 				
									100	Ι.					
								74	1						
								 A	\$						
	GE CardioSoft V6.73 (2)	V6.73 (2)			Unco	Unconfirmed			Atten	Attending MD:			MICE	MICRO MED CHARTS	Page 1

Selected Medians Report

Unconfirmed GE CardioSoft V6.73 (2) 10mm/mV 50Hz 0.01-20Hz S+ HEART V5.4

MICRO MED CHARTS
Page 2

Attending MD:

0.70

0.05

1.00

aVF

0.75

76.0

0.30

06.0

0.04

9/

UHID : CANN.0000229734 OP Visit No : CANNOPV380085 Conducted By: : Dr. ARULNITHI AYYANATHAN Conducted Date : 25-11-2023 16:37

Referred By : SELF

CARDIOLOGY

CARDIAC STRESS TEST – (TMT)

CARDIAC STRESS TEST - (TMT)
Angina Pectoria: NO
Previous MI: NO
PTCA: NO
CABG: NO
HTN: NO
DM: NO
Smoking: NO
Obesity: NO
Lipidemia: NO
Resting ECG Supine:
Standing:
Protocol Used:

UHID : CANN.0000229734 OP Visit No : CANNOPV380085 Conducted By: : Dr. ARULNITHI AYYANATHAN Conducted Date : 25-11-2023 16:37

Referred By : SELF

BRUCE

Monitoring Leads:

12 LEADS

Grade Achieved:

15

% HR / METS:

11.90

Reason for Terminating Test:

LEG DISCOMFORT

Total Exercise Time:

12.05

Symptoms and ECG Changes during Exercise:

NO SYMPTOMS NO SIGNIFICANT ST T CHANGES

0 mts:

NO SYMPTOMS NO SIGNIFICANT ST T CHANGES

3 mts:

NO SYMPTOMS NO SIGNIFICANT ST T CHANGES

6 mts:

NO SYMPTOMS NO SIGNIFICANT ST T CHANGES

INTERPRETATION:

Rhythm:

NORMAL

S.T. Segment:

NORMAL

III Blood Pressure Response:

UHID : CANN.0000229734 OP Visit No : CANNOPV380085 Conducted By: : Dr. ARULNITHI AYYANATHAN Conducted Date : 25-11-2023 16:37

Referred By : SELF

NORMAL

IV Fitness Response:

GOOD

Impression:

Cardiac stress analysis is NEGATIVE for inducible myocardial ischaemia

DR. ARULNITHI CARDIOLOGIST

---- END OF THE REPORT ----